APA (7th ed.) Citation

Pecora, A. L., Rapisuwon, S., Chen, K., Gardner, K., Cramer, G., Blair, D., . . . Atkins, M. B. (2023). Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma. Journal of clinical oncology, 41(16_suppl), 9563. https://doi.org/10.1200/JCO.2023.41.16_suppl.9563

Chicago Style (17th ed.) Citation

Pecora, Andrew L., et al. "Interim Analysis of a Phase II Study of Nivolumab/ipilimumab Plus Cabozantinib in Patients with Unresectable Advanced Melanoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): 9563. https://doi.org/10.1200/JCO.2023.41.16_suppl.9563.

MLA (9th ed.) Citation

Pecora, Andrew L., et al. "Interim Analysis of a Phase II Study of Nivolumab/ipilimumab Plus Cabozantinib in Patients with Unresectable Advanced Melanoma." Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, p. 9563, https://doi.org/10.1200/JCO.2023.41.16_suppl.9563.